​

Zentalis Pharmaceuticals (ZNTL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ZNTL Stock Forecast

Zentalis Pharmaceuticals (ZNTL) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $10.00, with a high of $10.00 and a low of $10.00. This represents a 184.09% increase from the last price of $3.52.

- $4 $8 $12 $16 $20 High: $10 Avg: $10 Low: $10 Last Closed Price: $3.52

ZNTL Stock Rating

Zentalis Pharmaceuticals stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (66.67%), 4 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 4 8 0 Strong Sell Sell Hold Buy Strong Buy

ZNTL Price Target Upside V Benchmarks

TypeNameUpside
StockZentalis Pharmaceuticals184.09%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts123
Avg Price Target$10.00$10.00$7.33
Last Closing Price$3.52$3.52$3.52
Upside/Downside184.09%184.09%108.24%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26-35--8
May, 26-45--9
Apr, 26-45--9
Mar, 26-45--9
Feb, 26-45--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 22, 2026Andrew FeinH.C. Wainwright$10.00$4.14141.55%184.09%
Apr 10, 2026Guggenheim$10.00$6.1462.87%184.09%
Nov 11, 2025Andrew BerensLeerink Partners$2.00$1.3251.52%-43.18%
Jun 18, 2024Akash TewariJefferies$6.00$4.3139.21%70.45%
Jun 18, 2024Matthew HarrisonMorgan Stanley$8.00$4.1493.24%127.27%
Jun 18, 2024Bradley CaninoStifel Nicolaus$10.00$5.3985.53%184.09%
Jun 18, 2024Robert DriscollWedbush$4.00$5.70-29.82%13.64%
May 07, 2024Bradley CaninoStifel Nicolaus$32.00$12.43157.44%809.09%
Nov 14, 2022Wedbush$32.00$22.5641.84%809.09%
Nov 11, 2022Morgan Stanley$55.00$20.90163.16%1462.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 22, 2026H.C. WainwrightBuyBuyhold
Apr 10, 2026GuggenheimBuyBuyhold
Nov 11, 2025Leerink PartnersMarket PerformMarket Performhold
Jan 29, 2025OppenheimerOutperformOutperformhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Sep 16, 2024OppenheimerOutperformOutperformhold
Aug 12, 2024WedbushHoldNeutralupgrade
Jun 20, 2024UBSNeutraldowngrade
Jun 18, 2024JefferiesHolddowngrade
Jun 18, 2024Morgan StanleyEqual-WeightHolddowngrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.47$-2.33$-1.91---
Avg Forecast$-4.41$-2.52$-2.90$-2.57$-2.33$-1.21
High Forecast$-3.93$-2.35$-2.40$-1.00$-1.57$-1.21
Low Forecast$-5.16$-2.72$-3.35$-3.51$-2.95$-1.21
Surprise %1.36%-7.54%-34.14%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$67.42M----
Avg Forecast-$40.62M$2.67M$23.02M$42.76M$175.34M
High Forecast-$40.98M$2.67M$23.02M$42.76M$175.34M
Low Forecast-$40.54M$2.67M$23.02M$42.76M$175.34M
Surprise %-65.99%----

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-292.19M$-165.84M$-137.06M---
Avg Forecast$-292.19M$-165.94M$-187.97M$-147.51M$-147.68M$-79.01M
High Forecast$-257.01M$-153.99M$-156.69M$-65.13M$-102.55M$-79.01M
Low Forecast$-337.33M$-177.89M$-219.24M$-229.88M$-192.82M$-79.01M
Surprise %--0.06%-27.08%---

ZNTL Forecast FAQ

Is Zentalis Pharmaceuticals stock a buy?

Zentalis Pharmaceuticals stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Zentalis Pharmaceuticals is a favorable investment for most analysts.

What is Zentalis Pharmaceuticals's price target?

Zentalis Pharmaceuticals's price target, set by 12 Wall Street analysts, averages $10 over the next 12 months. The price target range spans from $10 at the low end to $10 at the high end, suggesting a potential 184.09% change from the previous closing price of $3.52.

How does Zentalis Pharmaceuticals stock forecast compare to its benchmarks?

Zentalis Pharmaceuticals's stock forecast shows a 184.09% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Zentalis Pharmaceuticals over the past three months?

  • June 2026: 0% Strong Buy, 37.50% Buy, 62.50% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 0% Strong Buy, 44.44% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 0% Strong Buy, 44.44% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.

What is Zentalis Pharmaceuticals’s EPS forecast?

Zentalis Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.57, marking a 34.55% increase from the reported $-1.91 in 2025. Estimates for the following years are $-2.33 in 2027, and $-1.21 in 2028.

What is Zentalis Pharmaceuticals’s revenue forecast?

Zentalis Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $23.02M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $42.76M, and $175.34M for 2028.

What is Zentalis Pharmaceuticals’s net income forecast?

Zentalis Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-148M, representing an 7.62% increase from the reported $-137M in 2025. Projections indicate $-148M in 2027, and $-79.014M in 2028.